NCG and Next-Gen NCG Mice
With the advancement of gene editing technologies, an increasing number of immunodeficient mouse strains have been generated, which play a significant role in the field of immunology, oncology, stem cell biology, infectious diseases, and other applications. GemPharmatech has developed 26 severe immunodeficient mouse models for a myriad of scientific applications.
Our NCG portfolio is one of the most comprehensive sets of immunodeficient mouse models available for both non-profit and for-profit users, making it ideal for cancer immunotherapy research using cell derived xenograft (CDX), patient derived xenograft (PDX), and immune system reconstitution using human peripheral blood mononuclear cells (PBMC) as well as human hematopoietic stem cells (HSC). NCG and all strains of next-generation NCG mice are developed using CRISPR-Cas9 technology on pure inbred NOD/ShiLtJGpt background, by knocking out the Prkdc (Protein kinase, DNA activated, catalytic polypeptide) and Il2rg (interleukin-2 receptor subunit gamma) genes. Currently, we have 153 patient derived xenografts (PDXs) and 68 cell derived xenografts (CDXs) to accompany our NCG strains utilized in preclinical efficacy and safety studies.
Advantages of GemPharmatech’s Severe Immunodeficient Mouse Models
Our comprehensive portfolio of NCG and next-generation NCG mice enables excellent engraftment of human PBMCs, HSCs, and human tumor tissues.
Our proprietary NCG strains have an extended life span of greater than 90 weeks—approximately 15 weeks longer than for other severe immunodeficient mouse models.
One of our next-generation NCG strains, NCG-X, enables engraftment in the absence of irradiation, promising better animal health and reduced experimental complication.
Our large selection of PDXs provides preclinical tools for drug screening, biomarker development, and personalized medicine.
Our collection of CDXs provide a renewable source of patient tumor materials that can be used for a variety of research applications.
Traditional Immunodeficient Models
Severe Immunodeficient Models
Next-generation Severe Immunodeficient Models